|
CANDIDIASIS, FAMILIAL, 6
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
CANDIDIASIS, FAMILIAL, 6
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.
|
21350122 |
2011 |
|
CANDIDIASIS, FAMILIAL, 6
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.
|
21350122 |
2011 |
|
CANDIDIASIS, FAMILIAL, 6
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
GermlineCausalMutation
|
disease |
ORPHANET |
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.
|
21350122 |
2011 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
GeneticVariation
|
disease |
BEFREE |
Chronic mucocutaneous candidiasis disease (CMCD) may be caused by autosomal dominant (AD) IL-17F deficiency or autosomal recessive (AR) IL-17RA deficiency.
|
21727188 |
2011 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
BEFREE |
Patients with inborn errors of interleukin-17F (IL-17F) or IL-17RA display chronic mucocutaneous candidiasis (CMC).
|
24120361 |
2013 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
HPO |
|
|
|
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
BEFREE |
Chronic mucocutaneous candidiasis (CMC) is one of the three major disease components and is, to date, mainly explained by the presence of neutralizing auto-antibodies against cytokines [interleukin (IL)-17A, IL-17F, and IL-22] from T helper 17 cells, which are critical for the protection against fungal infections.
|
28919897 |
2017 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
BEFREE |
Examples include antigranulocyte macrophage-colony stimulating factor (GM-CSF) autoantibodies and pulmonary alveolar proteinosis; anti-interferon (IFN)-γ autoantibodies and disseminated nontuberculous mycobacteria (NTM); anti-interleukin-(IL)-6 autoantibodies and severe staphylococcal skin infection; anti-IL-17A, anti-IL-17F, or anti-IL-22 autoantibodies in patients with mucocutaneous candidiasis in the setting of both the autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED) syndrome and in cases of thymoma.
|
20966748 |
2010 |
|
Candidiasis, Chronic Mucocutaneous
|
0.450 |
Biomarker
|
disease |
BEFREE |
A recent study showed that autosomal dominant IL17F deficiency could cause chronic mucocutaneous candidiasis.
|
29458167 |
2018 |
|
Pancreatic carcinoma
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
22142827 |
2012 |
|
Pancreatic carcinoma
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genetic polymorphisms associated with pancreatic cancer survival: a genome-wide association study.
|
28470677 |
2017 |
|
Pancreatic carcinoma
|
0.110 |
Biomarker
|
disease |
BEFREE |
The variant 161R form of IL-17F is a natural antagonist of the antiangiogenic effects of wild-type 161H IL-17F, and angiogenesis may play an important role in the metastatic spread of pancreatic cancer.
|
22142827 |
2012 |
|
Pancreatic carcinoma
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
22142827 |
2012 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results highlight the potential role of MIF in the establishment of the chronic inflammatory process in RA via Th1 and Th17 cytokine profile induction and provide new evidence of the role of MIF to stimulate the IL-17A and IL-17F expression in PBMC from RA and CS.
|
30698113 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that future larger scale studies with increased power should be performed to determine if the IL-17F 7488A/G and the IL-17A G197A polymorphisms are associated with the disease activity in patients with RA.
|
26154773 |
2015 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
T-helper cells producing interleukin (IL)-17A and IL-17F cytokines (Th17 cells) are considered the source of autoimmunity in rheumatoid arthritis (RA).
|
26062018 |
2015 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the polymorphisms within the IL-17A and IL-17F genes play a significant role in RA.
|
25387578 |
2015 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Stratification according to demographic and clinical features revealed differential significant associations of IL17A-152 G/A, IL17F 7488 A/G and IL17F 7383 A/G polymorphisms within different subgroups and subtypes of clinical-pathologic features in RA patients.
|
28143790 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IL-17A (-197G/A) and IL-17F (7488T/C) polymorphisms are not associated with the susceptibility nor to the severity of RA and sSS in the studied population.
|
26232893 |
2016 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to compare the effects of interleukin (IL)-17A and IL-17F on gene expression and signalling in human rheumatoid arthritis (RA) synoviocytes.
|
21109515 |
2011 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In summary, our pooled analysis indicated that the IL-17A (rs2275913) and IL17F (rs763780 T/C) increased the RA risk.
|
28186427 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) and inadequate response (IR) to certolizumab pegol.
|
31177099 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Knowing this, the aim of this study was to investigate the association of +2199 A/C IL-23R (rs10889677), -197 G/A IL-17A (rs2275913), and +7488 A/G IL-17F (rs763780) gene polymorphisms with RA susceptibility and clinical features in a Brazilian population.
|
28547498 |
2017 |